Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:Bundle ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "bundlepackageleaflet-en-f34ab6116c3c4c0c8f28f2de9888b61e"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:identifier [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "None" ] ] ; # fhir:type [ fhir:v "document"] ; # fhir:timestamp [ fhir:v "2023-06-27T10:09:22Z"^^xsd:dateTime] ; # fhir:entry ( [ fhir:fullUrl [ fhir:v "Composition/composition-en-f34ab6116c3c4c0c8f28f2de9888b61e"^^xsd:anyURI ] ; ( fhir:resource <Composition/composition-en-f34ab6116c3c4c0c8f28f2de9888b61e> ) ] [ fhir:fullUrl [ fhir:v "MedicinalProductDefinition/mpf34ab6116c3c4c0c8f28f2de9888b61e"^^xsd:anyURI ] ; ( fhir:resource <MedicinalProductDefinition/mpf34ab6116c3c4c0c8f28f2de9888b61e> ) ] ) . # <Composition/composition-en-f34ab6116c3c4c0c8f28f2de9888b61e> a fhir:Composition ; fhir:id [ fhir:v "composition-en-f34ab6116c3c4c0c8f28f2de9888b61e"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-f34ab6116c3c4c0c8f28f2de9888b61e\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-f34ab6116c3c4c0c8f28f2de9888b61e</b></p><a name=\"composition-en-f34ab6116c3c4c0c8f28f2de9888b61e\"> </a><a name=\"hccomposition-en-f34ab6116c3c4c0c8f28f2de9888b61e\"> </a><a name=\"composition-en-f34ab6116c3c4c0c8f28f2de9888b61e-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/10/612/010</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - revolade</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/10/612/010" ] ] ) ; # fhir:status [ fhir:v "final"] ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package Leaflet" ] ] ; # fhir:category ( [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"^^xsd:anyURI ] ; fhir:code [ fhir:v "R" ] ; fhir:display [ fhir:v "Raw" ] ] ) ] ) ; # fhir:subject ( [ fhir:reference [ fhir:v "MedicinalProductDefinition/mpf34ab6116c3c4c0c8f28f2de9888b61e" ] ] ) ; # fhir:date [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime] ; # fhir:author ( [ fhir:reference [ fhir:v "Organization/mah-ema" ] ] ) ; # fhir:title [ fhir:v "TEST PURPOSES ONLY - revolade"] ; # fhir:attester ( [ fhir:mode [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/composition-attestation-mode"^^xsd:anyURI ] ; fhir:code [ fhir:v "official" ] ] ) ] ; fhir:time [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime ] ] ) ; # fhir:section ( [ fhir:title [ fhir:v "B. Package Leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "B. Package Leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>" ] ; fhir:emptyReason [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/list-empty-reason"^^xsd:anyURI ] ; fhir:code [ fhir:v "unavailable" ] ] ) ] ; ( fhir:section [ fhir:title [ fhir:v "Package leaflet: Information for the user" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package leaflet: Information for the user" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>" ] ] [ fhir:title [ fhir:v "What is in this leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "What is in this leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet:</p><ol type=\"1\"><li>What Revolade is and what it is used for</li><li>What you need to know before you take Revolade</li><li>How to take Revolade</li><li>Possible side effects</li><li>How to store Revolade</li><li>Contents of the pack and other information</li></ol></div>" ] ] [ fhir:title [ fhir:v "1. What revolade is and what it is used for" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "1. What revolade is and what it is used for" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Revolade contains eltrombopag, which belongs to a group of medicines called thrombopoietin-receptor agonists. It is used to help increase the number of platelets in your blood. Platelets are blood cells that help to reduce or prevent bleeding.</p><ul><li>Revolade is used to treat a bleeding disorder called immune (primary) thrombocytopenia (ITP) in patients aged 1 year and above who have already taken other medicines (corticosteroids or immunoglobulins), which have not worked.</li></ul><p>ITP is caused by a low blood platelet count (thrombocytopenia). People with ITP have an increased risk of bleeding. Symptoms patients with ITP may notice include petechiae (pinpoint- sized flat round red spots under the skin), bruising, nosebleeds, bleeding gums and not being able to control bleeding if they are cut or injured.</p><ul><li><p>Revolade can also be used to treat low platelet count (thrombocytopenia) in adults with hepatitis C virus (HCV) infections, if they have had problems with side effects while on interferon treatment. Many people with hepatitis C have low platelet counts, not only as a result of the disease, but also due to some of the antiviral medicines that are used to treat it. Taking Revolade may make it easier for you to complete a full course of antiviral medicine (peginterferon and ribavirin).</p></li><li><p>Revolade may also be used to treat adult patients with low blood counts caused by severe aplastic anaemia (SAA). SAA is a disease in which the bone marrow is damaged, causing a deficiency of the red blood cells (anaemia), white blood cells (leukopenia) and platelets (thrombocytopenia).</p></li></ul></div>" ] ] [ fhir:title [ fhir:v "2. What you need to know before you take revolade" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "2. What you need to know before you take revolade" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not take Revolade</p><ul><li>if you are allergic to eltrombopag or any of the other ingredients of this medicine (listed in section 6 under What Revolade contains ).</li></ul><p>Check with your doctor if you think this applies to you.</p><p>Warnings and precautions Talk to your doctor before taking Revolade:</p><ul><li>if you have liver problems. People who have low platelet counts as well as advanced chronic (long-term) liver disease are more at risk of side effects, including life-threatening liver damage and blood clots. If your doctor considers that the benefits of taking Revolade outweigh the risks, you will be closely monitored during treatment.</li><li>if you are at risk of blood clots in your veins or arteries, or you know that blood clots are common in your family. You may be at higher risk of blood clots:</li></ul><ul><li>as you get older</li><li>if you have had to stay in bed for a long time</li><li>if you have cancer</li><li>if you are taking the contraceptive birth control pill or hormone replacement therapy</li><li>if you have recently had surgery or received a physical injury</li><li>if you are very overweight (obese)</li><li>if you are a smoker</li><li>if you have advanced chronic liver disease</li></ul><p>If any of these apply to you, tell your doctor before starting treatment. You should not take Revolade unless your doctor considers that the expected benefits outweigh the risk of blood clots.</p><ul><li>if you have cataracts (the lens of the eye getting cloudy)</li><li>if you have another blood condition, such as myelodysplastic syndrome (MDS). Your doctor will carry out tests to check that you do not have this blood condition before you start Revolade. If you have MDS and take Revolade, your MDS may get worse.</li></ul><p>Tell your doctor if any of these apply to you.</p><p>Eye examinations Your doctor will recommend that you are checked for cataracts. If you do not have routine eye-tests your doctor should arrange regular testing. You may also be checked for the occurrence of any bleeding in or around your retina (the light-sensitive layer of cells at the back of the eye).</p><p>You will need regular tests Before you start taking Revolade, your doctor will carry out blood tests to check your blood cells, including platelets. These tests will be repeated at intervals while you are taking it.</p><p>Blood tests for liver function Revolade can cause blood test results that may be signs of liver damage - an increase of some liver enzymes, especially bilirubin and alanine / aspartate transaminases. If you are taking interferon-based treatments together with Revolade to treat low platelet count due to hepatitis C, some liver problems can get worse.</p><p>You will have blood tests to check your liver function before you start taking Revolade and at intervals while you are taking it. You may need to stop taking Revolade if the amount of these substances increases too much, or if you get other signs of liver damage.</p><p>Read the information Liver problems in section 4 of this leaflet.</p><p>Blood tests for platelet count If you stop taking Revolade, your blood platelet count is likely to become low again within several days. The platelet count will be monitored, and your doctor will discuss appropriate precautions with you. A very high blood platelet count may increase the risk of blood clotting. However blood clots can also form with normal or even low platelet counts. Your doctor will adjust your dose of Revolade to ensure that your platelet count does not become too high.</p><p>Get medical help immediately if you have any of these signs of a blood clot:</p><ul><li>swelling, pain or tenderness in one leg</li><li>sudden shortness of breath especially together with sharp pain in the chest or rapid breathing</li><li>abdominal (stomach) pain, enlarged abdomen, blood in your stools</li></ul><p>Tests to check your bone marrow In people who have problems with their bone marrow, medicines like Revolade could make the problems worse. Signs of bone marrow changes may show up as abnormal results in your blood tests. Your doctor may also carry out tests to directly check your bone marrow during treatment with Revolade.</p><p>Checks for digestive bleeding If you are taking interferon-based treatments together with Revolade you will be monitored for any signs of bleeding in your stomach or intestine after you stop taking Revolade.</p><p>Heart monitoring Your doctor may consider it necessary to monitor your heart during treatment with Revolade and carry out an electrocardiogram (ECG) test.</p><p>Older people (65 years and above) There are limited data on the use of Revolade in patients aged 65 years and older. Care should be taken when using Revolade if you are aged 65 years or above.</p><p>Children and adolescents Revolade is not recommended for children aged under 1 year who have ITP. It is also not recommended for people under 18 years with low platelet counts due to hepatitis C or severe aplastic anaemia.</p><p>Other medicines and Revolade Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without prescription and vitamins.</p><p>Some everyday medicines interact with Revolade including prescription and non-prescription medicines and minerals. These include:</p><ul><li>antacid medicines to treat indigestion, heartburn or stomach ulcers (see also When to take it<br/>in section 3)</li><li>medicines called statins, to lower cholesterol</li><li>some medicines to treat HIV infection, such as lopinavir and/or ritonavir</li><li>ciclosporin used in the context of transplantations or immune diseases</li><li>minerals such as iron, calcium, magnesium, aluminium, selenium and zinc which may be found in vitamin and mineral supplements (see also When to take it in section 3)</li><li>medicines such as methotrexate and topotecan, to treat cancer</li></ul><p>Talk to your doctor if you take any of these. Some of them are not to be taken with Revolade, or the dose may need adjusting, or you may need to alter the timing of when you take them. Your doctor will review the medicines you are taking, and suggest suitable replacements if necessary.</p><p>If you are also taking medicines to prevent blood clots there is a greater risk of bleeding. Your doctor will discuss this with you.</p><p>If you are taking corticosteroids, danazol, and/or azathioprine you may need to take a lower dose or to stop taking them while you are taking Revolade. Revolade with food and drink Do not take Revolade with dairy foods or drinks as the calcium in dairy products affects the absorption of the medicine. For more information, see When to take it in section 3. Pregnancy and breast-feeding Don t use Revolade if you are pregnant unless your doctor specifically recommends it. The effect of Revolade during pregnancy is not known.</p><ul><li>Tell your doctor if you are pregnant, think you may be pregnant, or are planning to have a baby.</li><li>Use a reliable method of contraception while you re taking Revolade, to prevent pregnancy</li><li>If you do become pregnant during treatment with Revolade, tell your doctor.</li></ul><p>Don t breast-feed while you are taking Revolade. It is not known whether Revolade passes into breast-milk.</p><p>If you are breast-feeding or planning to breast-feed, tell your doctor.</p><p>Driving and using machines Revolade can make you dizzy and have other side effects that make you less alert.</p><p>Don t drive or use machines unless you are sure you re not affected.</p><p>Revolade contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .</p></div>" ] ] [ fhir:title [ fhir:v "3. How to take revolade" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "3. How to take revolade" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Do not change the dose or schedule for taking Revolade unless your doctor or pharmacist advises you to. While you are taking Revolade, you will be under the care of a doctor with specialist experience in treating your condition.</p><p>How much to take For ITP Adults and children (6 to 17 years) the usual starting dose for ITP is one 50 mg tablet of Revolade a day. If you are of East-/Southeast-Asian origin you may need to start at a lower dose of 25 mg.</p><p>Children (1 to 5 years) the usual starting dose for ITP is one 25 mg tablet of Revolade a day.</p><p>For hepatitis C Adults - the usual starting dose for hepatitis C is one 25 mg tablet of Revolade a day. If you are of East-/Southeast-Asian origin you will start on the same 25 mg dose.</p><p>For SAA Adults - the usual starting dose for SAA is one 50 mg tablet of Revolade a day. If you are of East- /Southeast-Asian origin you may need to start at a lower dose of 25 mg.</p><p>Revolade may take 1 to 2 weeks to work. Based on your response to Revolade your doctor may recommend that your daily dose is changed.</p><p>How to take the tablets Swallow the tablet whole, with some water.</p><p>When to take it</p><p>Make sure that</p><ul><li>in the 4 hours before you take Revolade</li><li>and the 2 hours after you take Revolade</li></ul><p>you don t consume any of the following:</p><ul><li>dairy foods such as cheese, butter, yoghurt or ice cream</li><li>milk or milk shakes, drinks containing milk, yoghurt or cream</li><li>antacids, a type of medicine for indigestion and heartburn</li><li>some mineral and vitamin supplements including iron, calcium, magnesium, aluminium, selenium and zinc</li></ul><p>If you do, the medicine will not be properly absorbed into your body.</p><p>For more advice about suitable foods and drinks, talk to your doctor.</p><p>If you take more Revolade than you should Contact a doctor or pharmacist immediately. If possible show them the pack, or this leaflet. You will be monitored for any signs or symptoms of side effects and given appropriate treatment immediately.</p><p>If you forget to take Revolade Take the next dose at the usual time. Do not take more than one dose of Revolade in one day.</p><p>If you stop taking Revolade Don t stop taking Revolade without talking to your doctor. If your doctor advises you to stop treatment, your platelet count will then be checked each week for four weeks. See also Bleeding or bruising after you stop treatment in section 4. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>" ] ] [ fhir:title [ fhir:v "4. Possible side effects" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "4. Possible side effects" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Symptoms needing attention: see a doctor People taking Revolade for either ITP or low blood platelet counts due to hepatitis C could develop signs of potentially serious side effects. It is important to tell a doctor if you develop these symptoms.</p><p>NO dairy products, antacids or mineral supplements Take Revolade For 4 hours before you<br/>take Revolade... ... and for 2 hours after Higher risk of blood clots Certain people may have a higher risk of blood clots, and medicines like Revolade could make this problem worse. The sudden blocking of a blood vessel by a blood clot is an uncommon side effect and may affect up to 1 in 100 people.</p><p>Get medical help immediately if you develop signs and symptoms of a blood clot, such as:</p><ul><li>swelling, pain, heat, redness, or tenderness in one leg</li><li>sudden shortness of breath, especially together with sharp pain in the chest or rapid breathing</li><li>abdominal (stomach) pain, enlarged abdomen, blood in your stools.</li></ul><p>Liver problems Revolade can cause changes that show up in blood tests, and may be signs of liver damage. Liver problems (increased enzymes showing up in blood tests) are common and may affect up to 1 in 10 people. Other liver problems are uncommon and may affect up to 1 in 100 people.</p><p>If you have either of these signs of liver problems:</p><ul><li>yellowing of the skin or the whites of the eyes (jaundice)</li><li>unusually dark-coloured urine</li></ul><p>tell your doctor immediately.</p><p>Bleeding or bruising after you stop treatment Within two weeks of stopping Revolade, your blood platelet count will usually drop back down to what it was before starting Revolade. The lower platelet count may increase the risk of bleeding or bruising. Your doctor will check your platelet count for at least 4 weeks after you stop taking Revolade.</p><p>Tell your doctor if you have any bleeding or bruising after stopping Revolade.</p><p>Some people have bleeding in the digestive system after they stop taking peginterferon, ribavirin, and Revolade. Symptoms include:</p><ul><li>black tarry stools (discoloured bowel movements are a uncommon side effect that may affect up to 1 in 100 people)</li><li>blood in your stools</li><li>vomiting blood or something that looks like coffee grounds</li></ul><p>Tell your doctor immediately if you have any of these symptoms.</p><p>The following side effects have been reported to be associated with treatment with Revolade in adult patients with ITP:</p><p>Very common side effects These may affect more than 1 in 10 people:</p><ul><li>common cold</li><li>feeling sick (nausea)</li><li>diarrhoea</li><li>cough</li><li>infection in the nose, sinuses, throat and upper airways (upper respiratory tract infection)</li><li>back pain</li></ul><p>Very common side effects that may show up in blood tests:</p><ul><li>increased of liver enzymes (alanine aminotransferase (ALT))</li></ul><p>Common side effects These may affect up to 1 in 10 people:</p><ul><li>muscle pain, muscle spasm, muscle weakness</li><li>bone pain</li><li>heavy menstrual period</li><li>sore throat and discomfort when swallowing</li><li>eye problems including abnormal eye test, dry eye, eye pain and blurred vision</li><li>vomiting</li><li>flu (influenza)</li><li>cold sore</li><li>pneumonia</li><li>irritation and inflammation (swelling) of the sinuses</li><li>inflammation (swelling) and infection of the tonsils,</li><li>infection of the lungs, sinuses, nose and throat</li><li>inflammation of the gum tissue</li><li>loss of appetite</li><li>feeling of tingling, prickling or numbness, commonly called pins and needles</li><li>decreased skin sensations</li><li>feeling drowsy</li><li>ear pain</li><li>pain, swelling and tenderness in one of your legs (usually the calf) with warm skin in the affected area (signs of a blood clot in a deep vein)</li><li>localised swelling filled with blood from a break in a blood vessel (haematoma)</li><li>hot flushes</li><li>mouth problems including dry mouth, sore mouth, sensitive tongue, bleeding gums, mouth ulcers</li><li>runny nose</li><li>toothache</li><li>abdominal pain</li><li>abnormal liver function</li><li>skin changes including excessive sweating, itching bumpy rash, red spots, changes in appearance of the skin</li><li>hair loss</li><li>foamy, frothy or bubbly-looking urine (signs of protein in urine)</li><li>high temperature, feeling hot</li><li>chest pain</li><li>feeling weak</li><li>problems sleeping, depression</li><li>migraine</li><li>decreased vision</li><li>spinning sensation (vertigo)</li><li>digestive wind/gas</li></ul><p>Common side effects that may show up in blood test:</p><ul><li>decreased number of red blood cells (anaemia)</li><li>decreased number of platelets (thrombocytopenia)</li><li>decreased number of white blood cells</li><li>decreased haemoglobin level</li><li>increased number of eosinophils</li><li>increased number of white blood cells (leukocytosis)</li><li>increased levels of uric acid</li><li>decreased levels of potassium</li><li>increased levels of creatinine</li><li>increased levels of alkaline phosphatase</li><li>increase of liver enzymes (aspartate aminotransferase (AST))</li><li>increase in blood bilirubin (a substance produced by the liver)</li><li>increased levels of some proteins</li></ul><p>Uncommon side effects These may affect up to 1 in 100 people:</p><ul><li>allergic reaction</li><li>interruption of blood supply to part of the heart</li><li>sudden shortness of breath, especially when accompanied with sharp pain in the chest and /or rapid breathing, which could be signs of a blood clot in the lungs (see Higher risk of blood clots earlier in section 4)</li><li>the loss of function of part of the lung caused by a blockage in the lung artery</li><li>possible pain, swelling, and/or redness around a vein which could be signs of blood clot in a vein</li><li>yellowing of the skin and/or abdominal pain which could be signs of a blockage in the bile tract, lesion on liver, liver damage due to inflammation (see Liver problems earlier in section 4)</li><li>liver injury due to medication</li><li>heart beating faster, irregular heartbeat, bluish discolouration of the skin, disturbances of heart rhythm (QT prolongation) which could be signs of a disorder related to the heart and the blood vessels</li><li>blood clot</li><li>flushing</li><li>painful swollen joints caused by uric acid (gout)</li><li>lack of interest, mood changes, crying that is difficult to stop, or occurs at unexpected times</li><li>problems with balance, speech and nerve function, shaking</li><li>painful or abnormal skin sensations</li><li>paralysis on one side of the body</li><li>migraine with aura</li><li>nerve damage</li><li>dilation or swelling of blood vessels that cause headache</li><li>eye problems including increased production of tears, cloudy lens in the eye (cataract), bleeding of the retina, dry eyes</li><li>problems with the nose, throat and sinuses, breathing problems when sleeping</li><li>mouth and throat blisters/sores</li><li>loss of appetite</li><li>digestive system problems including frequent bowel movements, food poisoning, blood in stool, vomiting of blood</li><li>rectal bleeding, change in stool colour, abdominal bloating, constipation</li><li>mouth problems, including dry or sore mouth, tongue pain, bleeding gums, discomfort in mouth</li><li>sunburn</li><li>feeling hot, feeling anxious</li><li>redness or swelling around a wound</li><li>bleeding around a catheter (if present) into the skin</li><li>sensation of a foreign body</li><li>kidney problems including inflammation of the kidney, excessive urination at night, kidney failure, white cells in urine</li><li>cold sweat</li><li>generally feeling unwell</li><li>infection of the skin</li><li>skin changes including skin discolouration, peeling, redness, itching and sweating</li><li>muscular weakness</li><li>cancer of rectum and colon</li></ul><p>Uncommon side effects that may show up in laboratory tests:</p><ul><li>changes in the shape of red blood cells</li><li>presence of developing white blood cells which may be indicative of certain diseases</li><li>increased number of platelets</li><li>decreased levels of calcium</li><li>decreased number of red blood cells (anaemia) caused by excessive destruction of red blood cells (haemolytic anaemia)</li><li>increased number of myelocytes</li><li>increased band neutrophils</li><li>increased blood urea</li><li>increased levels of protein in urine</li><li>increased levels of blood albumin</li><li>increased levels of total protein</li><li>decreased levels of blood albumin</li><li>increased pH of urine</li><li>increased level of haemoglobin</li></ul><p>The following additional side effects have been reported to be associated with treatment with Revolade in children (aged 1 to 17 years) with ITP: If these side effects become severe, please tell your doctor, pharmacist or nurse.</p><p>Very common side effects These may affect more than 1 in 10 children:</p><ul><li>infection in the nose, sinuses, throat and upper airways, common cold (upper respiratory tract infection)</li><li>diarrhoea</li><li>abdominal pain</li><li>cough</li><li>high temperature</li><li>feeling sick (nausea)</li></ul><p>Common side effects These may affect up to 1 in 10 children:</p><ul><li>difficulty in sleeping (insomnia)</li><li>toothache</li><li>pain in the nose and throat</li><li>itchy, runny or blocked nose</li><li>sore throat, runny nose, nasal congestion and sneezing</li><li>mouth problems including dry mouth, sore mouth, sensitive tongue, bleeding gums, mouth ulcers</li></ul><p>The following side effects have been reported to be associated with treatment with Revolade in combination with peginterferon and ribavirin in patients with HCV:</p><p>Very common side effects These may affect more than 1 in 10 people:</p><ul><li>headache</li><li>loss of appetite</li><li>cough</li><li>feeling sick (nausea), diarrhoea</li><li>muscle pain, muscle weakness</li><li>itching</li><li>feeling tired</li><li>fever</li><li>unusual hair loss</li><li>feeling weak</li><li>flu-like illness</li><li>swelling in the hands or feet</li><li>chills</li></ul><p>Very common side effects that may show up in blood tests:</p><ul><li>decreased number of red blood cells (anaemia)</li></ul><p>Common side effects These may affect up to 1 in 10 people:</p><ul><li>infection of the urinary system</li><li>inflammation of the nasal passages, throat and mouth, flu-like symptoms, dry mouth, sore or inflamed mouth, toothache</li><li>weight loss</li><li>sleep disorders, abnormal drowsiness, depression, anxiety</li><li>dizziness, problems with attention and memory, change in mood</li><li>decreased brain function further to liver injury</li><li>tingling or numbness of the hands or feet</li><li>fever, headache</li><li>eye problems, including cloudy lens in the eye (cataract), dry eye, small yellow deposits in the retina, yellowing of the whites of the eye</li><li>bleeding of the retina</li><li>spinning sensation (vertigo)</li><li>fast or irregular heartbeat (palpitations), shortness of breath</li><li>cough bringing up phlegm, runny nose, flu (influenza), cold sore, sore throat and discomfort when swallowing</li><li>digestive system problems, including vomiting, stomach pain, indigestion, constipation, swollen stomach, taste disturbances, piles (haemorrhoids), stomach pain/discomfort, swollen blood vessels and bleeding in the gullet (oesophagus)</li><li>toothache</li><li>liver problems, including tumour in the liver, yellowing of the whites of the eyes or skin (jaundice), liver injury due to medication (see Liver problems earlier in section 4)</li><li>skin changes, including rash, dry skin, eczema, redness of the skin, itching, excessive sweating, unusual skin growths, hair loss</li><li>joint pain, back pain, bone pain, pain in extremities (arms, legs, hands or feet), muscle spasms</li><li>irritability, generally feeling unwell, skin reaction such as redness or swelling and pain at the site of injection, chest pain and discomfort, build-up of fluid in the body or extremities causing swelling</li><li>infection in the nose, sinuses, throat and upper airways, common cold (upper respiratory tract infection), inflammation of mucous membrane lining the bronchi</li><li>depression, anxiety, sleep problems, nervousness Common side effects that may show up in blood tests:</li><li>increased blood sugar (glucose)</li><li>decreased number of white blood cells</li><li>decreased number of neutrophils</li><li>decreased level of blood albumin</li><li>decreased level of haemoglobin</li><li>increased levels of blood bilirubin (a substance produced by the liver)</li><li>changes in the enzymes that control blood clotting</li></ul><p>Uncommon side effects These may affect up to 1 in 100 people:</p><ul><li>painful urination</li><li>disturbances of heart rhythm (QT prolongation)</li><li>stomach flu (gastroenteritis), sore throat</li><li>mouth blisters/sores, inflammation of the stomach</li><li>skin changes including change in colour, peeling, redness, itching, lesion and night sweats</li><li>blood clots in a vein to the liver (possible liver and/or digestive system damage)</li><li>abnormal blood clotting in small blood vessels with kidney failure</li><li>rash, bruising at the injection site, chest discomfort</li><li>decreased number of red blood cells (anaemia) caused by excessive destruction of red blood cells (haemolytic anaemia)</li><li>confusion, agitation</li><li>liver failure</li></ul><p>The following side effects have been reported to be associated with treatment with Revolade in patients with severe aplastic anaemia (SAA): If these side effects become severe, please tell your doctor, pharmacist or nurse.</p><p>Very common side effects These may affect more than 1 in 10 people.</p><ul><li>cough</li><li>headache</li><li>mouth and throat pain</li><li>diarrhoea</li><li>feeling sick (nausea)</li><li>joint pain (arthralgia)</li><li>pain in extremities (arms, legs, hands and feet)</li><li>dizziness</li><li>feeling very tired</li><li>fever</li><li>chills</li><li>itchy eyes</li><li>blisters in the mouth</li><li>bleeding of the gums</li><li>abdominal pain</li><li>muscle spasms</li></ul><p>Very common side effects that may show up in the blood tests</p><ul><li>abnormal changes to the cells in your bone marrow</li><li>increased levels of liver enzymes (aspartate aminotransferase (AST))</li></ul><p>Common side effects These may affect up to 1 in 10 people.</p><ul><li>anxiety</li><li>depression</li><li>feeling cold</li><li>generally feeling unwell</li><li>eye problems including vision problems, blurred vision, cloudy lens in the eye (cataract), spots or deposits in eye (vitreous floaters), dry eye, itchy eye, yellowing of the whites of the eyes or skin</li><li>nose bleed</li><li>digestive system problems including difficulty swallowing, mouth pain, swollen tongue, vomiting, loss of appetite, stomach pain/discomfort, swollen stomach, digestive wind/gas, constipation, intestinal motility disorder which can cause contipation, bloating, diarrhea and/or above mentioned symptoms, change in stool colour</li><li>fainting</li><li>skin problems including small red or purple spots caused by bleeding into the skin (petechiae) rash, itching, hives, skin lesion</li><li>back pain</li><li>muscle pain</li><li>bone pain</li><li>weakness (asthenia)</li><li>swelling of the lower limbs due to the accumulation of fluids</li><li>abnormal colored urine</li><li>interruption in blood supply to spleen (splenic infarction)</li><li>runny nose</li></ul><p>Common side effects that may show up in the blood tests</p><ul><li>increase in enzymes due to muscle breakdown (creatine phosphokinase)</li><li>accumulation of iron in the body (iron overload)</li><li>decrease in blood sugar levels (hypoglycaemia)</li><li>increased levels of blood bilirubin (a substance produced by the liver)</li><li>decreased levels of white blood cells</li></ul><p>Side effects with frequency not known Frequency cannot be estimated from the available data</p><ul><li>skin discolouration</li><li>darkening of the skin</li><li>liver injury due to medication</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>" ] ] [ fhir:title [ fhir:v "5. How to store revolade" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "5. How to store revolade" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and the blister.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>" ] ] [ fhir:title [ fhir:v "6. Contents of the pack and other information" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "6. Contents of the pack and other information" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Revolade contains The active substance in Revolade is eltrombopag.</p><p>12.5 mg film-coated tablets Each film-coated tablet contains eltrombopag olamine equivalent to 12.5 mg eltrombopag.</p><p>25 mg film-coated tablets Each film-coated tablet contains eltrombopag olamine equivalent to 25 mg eltrombopag.</p><p>50 mg film-coated tablets Each film-coated tablet contains eltrombopag olamine equivalent to 50 mg eltrombopag.</p><p>75 mg film-coated tablets Each film-coated tablet contains eltrombopag olamine equivalent to 75 mg eltrombopag.</p><p>The other ingredients are: hypromellose, macrogol 400, magnesium stearate, mannitol (E421), microcrystalline cellulose, povidone, sodium starch glycolate, titanium dioxide (E171).</p><p>Revolade 12.5 mg and 25 mg film-coated tablets also contain polysorbate 80 (E433).</p><p>Revolade 50 mg film-coated tablets also contain iron oxide red (E172) and iron oxide yellow (E172).</p><p>Revolade 75 mg film-coated tablets also contain iron oxide red (E172) and iron oxide black (E172).</p><p>What Revolade looks like and contents of the pack Revolade 12.5 mg film-coated tablets are round, biconvex, white, debossed with GS MZ1 and 12.5<br/>on one side.</p><p>Revolade 25 mg film-coated tablets are round, biconvex, white, debossed with GS NX3 and 25 on one side.</p><p>Revolade 50 mg film-coated tablets are round, biconvex, brown, debossed with GS UFU and 50 on one side.</p><p>Revolade 75 mg film-coated tablets are round, biconvex, pink, debossed with GS FFS and 75 on one side.</p><p>They are supplied in aluminum blisters in a carton containing 14 or 28 film-coated tablets and multipacks containg 84 (3 packs of 28) film-coated tablets).</p><p>Not all pack sizes may be available in your country.</p><p>Marketing authorisation holder Novartis Europharm Limited Vista Building Elm Park, Merrion Road Dublin 4 Ireland</p><p>Manufacturer Lek d.d Verovskova Ulica Ljubljana 1Slovenia</p><p>Novartis Pharmaceutical Manufacturing LLC Verovskova Ulica Ljubljana 1Slovenia</p><p>Novartis Farmac utica SA Gran Via de les Corts Catalanes, 08013 Barcelona Spain</p><p>Novartis Pharma GmbH Roonstra e D-90429 Nuremberg Germany</p><p>Glaxo Wellcome S.A. Avenida de Extremadura 3 09400 Aranda de Duero Burgos Spain</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Novartis Pharma N.V. T l/Tel: +32 2 246 16 Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16<br/>Novartis Bulgaria EOOD : +359 2 489 98 Luxembourg/Luxemburg Novartis Pharma N.V. T l/Tel: +32 2 246 16 esk republika Novartis s.r.o. Tel: +420 225 775 Magyarorsz g Novartis Hung ria Kft. Tel.: +36 1 457 65 Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 Malta Novartis Pharma Services Inc. Tel: +356 2122 2Deutschland Novartis Pharma GmbH Tel: +49 911 273 0</p><p>Nederland Novartis Pharma B.V. Tel: +31 88 04 52 Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 Norge Novartis Norge AS Tlf: +47 23 05 20<br/>Novartis (Hellas) A.E.B.E. : +30 210 281 17 sterreich Novartis Pharma GmbH Tel: +43 1 86 6Espa a Novartis Farmac utica, S.A. Tel: +34 93 306 42 Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4France Novartis Pharma S.A.S. T l: +33 1 55 47 66 Portugal Novartis Farma - Produtos Farmac uticos, S.A. Tel: +351 21 000 8Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 Rom nia Novartis Pharma Services Romania SRL Tel: +40 21 31299 Ireland Novartis Ireland Limited Tel: +353 1 260 12 Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 sland Vistor hf. S mi: +354 535 7Slovensk republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133<br/>Novartis Pharma Services Inc. : +357 22 690 Sverige Novartis Sverige AB Tel: +46 8 732 32 Latvija SIA Novartis Baltics Tel: +371 67 887 United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>" ] ] ) ] ) . # <MedicinalProductDefinition/mpf34ab6116c3c4c0c8f28f2de9888b61e> a fhir:MedicinalProductDefinition ; fhir:id [ fhir:v "mpf34ab6116c3c4c0c8f28f2de9888b61e"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi> ] ) ] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mpf34ab6116c3c4c0c8f28f2de9888b61e\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mpf34ab6116c3c4c0c8f28f2de9888b61e</b></p><a name=\"mpf34ab6116c3c4c0c8f28f2de9888b61e\"> </a><a name=\"hcmpf34ab6116c3c4c0c8f28f2de9888b61e\"> </a><a name=\"mpf34ab6116c3c4c0c8f28f2de9888b61e-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/10/612/010</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Revolade 12.5 mg film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/10/612/010" ] ] ) ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "MedicinalProduct" ] ; fhir:display [ fhir:v "Medicinal Product" ] ] ) ] ; # fhir:domain [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-domain"^^xsd:anyURI ] ; fhir:code [ fhir:v "Human" ] ; fhir:display [ fhir:v "Human use" ] ] ) ] ; # fhir:status [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/publication-status"^^xsd:anyURI ] ; fhir:code [ fhir:v "active" ] ; fhir:display [ fhir:v "active" ] ] ) ] ; # fhir:legalStatusOfSupply [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000072084" ] ; fhir:display [ fhir:v "Medicinal product subject to medical prescription" ] ] ) ] ; # fhir:name ( [ fhir:productName [ fhir:v "Revolade 12.5 mg film-coated tablets" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000001" ] ; fhir:display [ fhir:v "Full name" ] ] ) ] ; ( fhir:part [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000002" ] ; fhir:display [ fhir:v "Invented name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000003" ] ; fhir:display [ fhir:v "Scientific name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000004" ] ; fhir:display [ fhir:v "Strength part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000005" ] ; fhir:display [ fhir:v "Pharmaceutical dose form part" ] ] ) ] ] ) ; ( fhir:usage [ fhir:country [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:jurisdiction [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:language [ ( fhir:coding [ fhir:system [ fhir:v "urn:ietf:bcp:47"^^xsd:anyURI ] ; fhir:code [ fhir:v "en" ] ; fhir:display [ fhir:v "en" ] ] ) ] ] ) ] ) . #
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
